Glutathione, glutathione S-transferase α and π, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer

Gynecologic Oncology

Volumn 65, Issue 1, 1997, Pages 54-62

  Tanner, Berno ^a   Hengstler, Jan Georg ^a   Dietrich, Britta ^a   Henrich, Michael ^a   Steinberg, Pablo ^a   Weikel, Wolfgang ^a   Meinert, Rolf ^a   Kaina, Bernd ^a   Oesch, Franz ^a   Knapstein, Paul Georg ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CARBOPLATIN; CYCLOPHOSPHAMIDE; GLUTATHIONE; GLUTATHIONE TRANSFERASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG RESISTANCE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

EID: 0031127928     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4593     Document Type: Article

References (38)

1. 1. Ozols RF, O'Dwyer PJ, Hamilton TC: Clinical reversal of drug resistance on ovarian cancer. Gynecol Oncol 51:90-96, 1993
2. 2. Johnson SW, Ozols RF, Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71:644-649, 1993
3. 3. Ozols RF, O'Dwyer PJ, Hamilton TC: Drug Resistance in Ovarian Cancer, in Markman M, Hoskins WJ (eds): Cancer of the Ovary. New York, Raven Press, 1993, pp 261-276
4. 4. Andrews P, Velury S, Man, et al: Cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:68-73, 1988
5. 5. Lai G-M, Ozols RF, Smyth JF, et al: Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 37:4597-4600, 1988
6. 6. Masuda H, Ozols RF, Lai G-M, et al: Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48:5713-5716, 1988
7. 7. Eastman A, Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 27:4730-4734, 1988
8. 8. Mistry P, Kelland LR, Abel G, Sidhar S, Harrop KR: The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64:215-220, 1991
9. 9. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, et al: Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 35:2583-2586, 1985
10. 10. Tew K, Clapper M: Glutathione S-Transferases and Anticancer Drug Resistance, in Woolley PV III, Tew KD (eds): Mechanisms of Drug Resistance in Neoplastic Cells. San Diego, Academic Press, 1988, pp 141-157
11. 11. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813-1815, 1988
12. 12. Kasahara K, Fujiware Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, et al: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51:3237-3242, 1991
13. 13. Cox PJ, Phillips BJ, Thomas P: The enzymatic basis of the selective action of cyclophosphamide. Cancer Res 35:3755-3761, 1975
14. 14. Hipkens JH, Struck RF, Gurtoo HL: Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. Cancer Res 41:3571-3583, 1981
15. 15. Cox PJ, Phillips BJ, Thomas P: Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes. Cancer Treat Rep 60:321-326, 1976
16. 16. Serov SF, Scully RE: Histological Typing of Ovarian Tumors, in International Histological Classification of Tumors, No. 9. Geneva, WHO, 1973
17. 17. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50:1-7, 1971
18. 18. Griffith OW: Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridene. Anal Biochem 106:207-212, 1980
19. 19. Oesch F, Hengstler JG, Fuchs J: Cigarette smoking protects mononuclear blood cells of carcinogen exposed workers from additional work-exposure induced DNA single strand breaks. Mutat Res 321:175-185, 1994
20. 20. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 27:502-522, 1969
21. 21. Kalbfleisch JD, Prentice RC: The Statistical Analysis of Failure Time Data, New York, Wiley, 1980
22. 22. Hollander M, Wolfe DA: Nonparametric Statistical Methods, New York, Wiley, 1973
23. 23. van der Zee AG, Hollema HH, de Druijn HW, Willemse PH, Boonstra H, Mulder NH, Aalders JG, de Vries EG: P-Glycoprotein expression and DNA topisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51:5915-5920, 1992
24. 24. Ghazal-Aswad S, Hogarth L, Hall AG, George M, Sinha DP, Lind M, Calvert AH, Sunter JP, Newell DR: The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Br J Cancer 74:468-473, 1996
25. 25. Hamilton TC, Lai G, Rothenberg M, et al: Mechanisms of Resistance to Cisplatin and Alkylating Agents, in Ozols R (ed): Drug Resistance in Cancer Therapy. Boston, Kluwer Academic, 1989, pp 151-169
26. 26. Ozols RF, Louie K, Plowman J, et al: Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 36:147-153, 1987
27. 27. Meister A: Novel Drugs That Affect Glutathione Metabolism, in Wooley PV III, Tew KD (eds): Mechanisms of Drug Resistance in Neoplastic Cells. San Diego, Academic Press, 1988, pp 99-126
28. 28. Louie K, Behrens B, Kinsella T, et al: Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110-2115, 1985
29. 29. Perry RR, Mazetta JA, Levin M, Barranco SC: Glutathione levels and variability in breast tumors and normal tissue. Cancer 72:783-787, 1993
30. 30. O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew KD, Padovic K, Comis RL, Ozols RF: Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results. J Natl Cancer Inst 84:1601-1602, 1992
31. 31. Britten RA, Green JA, Warenius HM: Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Physiol 24:527-531, 1992
32. 32. Clapper MJ, Hoffmann J, Tew K: Sensitization of human colon xenografts to L-phenylalanine mustard using ethacrynic acid. J Cell Pharmacol 1:71-78, 1990
33. 33. Lee FY, Vessey A, Rofstad E, Siemann DW, Sutherland RM: Heterogeneity of glutathione content in human ovarian cancer. Cancer Res 49:5244-5248, 1989
34. 34. Lau DH, Lewis AD, Ehsan MN, Sikic BI: Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51:5181-5187, 1991
35. 35. Hoban PA, Robson CN, Davies SM, Hall AG, Cattan AR, Hickson ID, Harris AL: Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochem Pharmacol 43:685-689, 1992
36. 36. Green JA, Robertson LJ, Clark AH: Glutathione S-transferase expression in benign and malignant ovarian tumors. Br J Cancer 68:235-239, 1993
37. 37. Hamada S, Kamada M, Furumoto H, Hirao T, Aono T: Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 52:313-319, 1994
38. 38. van der Zee AG, van Ommen B, Meijer C, Hollema H, van Bladeren PJ, de Vries EG: Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumors, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer 66:930-936, 1992